Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients
Nita L. Seibel(National Cancer Institute), Thomas J. Walsh(Cornell University), Donald N. Buell(Astellas Pharma (Japan)), Antonio Arrieta(Children's Hospital of Orange County), Edith Albano(Children's Hospital Colorado), James J. Keirns(Boehringer Ingelheim (United States)), D. Facklam(Astellas Pharma (Japan)), W. Lau(Astellas Pharma (Japan)), Patricia M. Flynn(St. Jude Children's Research Hospital), Aziza Shad(Georgetown University), Cindy L. Schwartz(Brown University)
Cited by 246
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k